PT  - JOURNAL ARTICLE
AU  - Jeremie Calais
AU  - Amar U. Kishan
AU  - Minsong Cao
AU  - Wolfgang P. Fendler
AU  - Matthias Eiber
AU  - Ken Herrmann
AU  - Francesco Ceci
AU  - Robert E. Reiter
AU  - Matthew B. Rettig
AU  - John V. Hegde
AU  - Narek Shaverdian
AU  - Chris R. King
AU  - Michael L. Steinberg
AU  - Johannes Czernin
AU  - Nicholas G. Nickols
TI  - Potential Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
AID  - 10.2967/jnumed.118.209387
DP  - 2018 Nov 01
TA  - Journal of Nuclear Medicine
PG  - 1714--1721
VI  - 59
IP  - 11
4099  - http://jnm.snmjournals.org/content/59/11/1714.short
4100  - http://jnm.snmjournals.org/content/59/11/1714.full
SO  - J Nucl Med2018 Nov 01; 59
AB  - Standard-of-care imaging for initial staging of prostate cancer (PCa) underestimates disease burden. Prostate-specific membrane antigen (PSMA) PET/CT detects PCa metastasis with superior accuracy, having a potential impact on the planning of definitive radiation therapy (RT) for nonmetastatic PCa. Our objectives were to determine how often definitive RT planning based on standard target volumes covers 68Ga-PSMA-11 PET/CT–defined disease and to assess the potential impact of 68Ga-PSMA-11 PET/CT on definitive RT planning. Methods: This was a post hoc analysis of an intention-to-treat population of 73 patients with localized PCa without prior local therapy who underwent 68Ga-PSMA PET/CT for initial staging as part of an investigational new drug trial. Eleven of the 73 were intermediate-risk (15%), 33 were high-risk (45%), 22 were very-high-risk (30%), and 7 were N1 (9.5%). Clinical target volumes (CTVs), which included the prostate, seminal vesicles, and (in accord with the Radiation Therapy Oncology Group consensus guidelines) pelvic lymph nodes (LNs), were contoured on the CT portion of the PET/CT images by a radiation oncologist masked to the PET findings. 68Ga-PSMA-11 PET/CT images were analyzed by a nuclear medicine physician. 68Ga-PSMA-11–positive lesions not covered by planning volumes based on the CTVs were considered to have a major potential impact on treatment planning. Results: All patients had one or more 68Ga-PSMA-11–positive primary prostate lesions. Twenty-five (34%) and 7 (9.5%) of the 73 patients had 68Ga-PSMA-11–positive pelvic LN and distant metastases, respectively. The sites of LN metastases in decreasing order of frequency were external iliac (20.5%), common iliac (13.5%), internal iliac (12.5%) obturator (12.5%), perirectal (4%), abdominal (4%), upper diaphragm (4%), and presacral (1.5%). The median size of the LN lesions was 6 mm (range, 4–24 mm). RT planning based on the CTVs covered 69 (94.5%) of the 73 primary lesions and 20 (80%) of the 25 pelvic LN lesions, on a per-patient analysis. Conclusion: 68Ga-PSMA-11 PET/CT had a major impact on intended definitive RT planning for PCa in 12 (16.5%) of the 73 patients whose RT fields covered the prostate, seminal vesicles, and pelvic LNs and in 25 (37%) of the 66 patients whose RT fields covered the prostate and seminal vesicles but not the pelvic LNs.